Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XIAP | P98170 | 9/20 | 0.36 |
| ▸ | GHSR | Q92847 | 5/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.32 |
| ▸ | SOAT2 | O75908 | 1/20 | 0.31 |
| ▸ | ACAT1 | P24752 | 1/20 | 0.31 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3609708 | 0.90 | XIAP (0.38) | XIAPGHSR | |
| SCHEMBL3603775 | 0.89 | GHSR (0.33) | XIAPGHSRCYP2D6S1PR1SOAT2 | |
| SCHEMBL3616206 | 0.84 | XIAP (0.37) | XIAP | |
| Hydrochloric Acid SCHEMBL3612487 | 0.83 | XIAP (0.37) | XIAP | |
| SCHEMBL3610348 | 0.82 | GHSR (0.33) | XIAPGHSR | |
| SCHEMBL3601495 | 0.81 | XIAP (0.45) | XIAP | |
| Hydrochloric Acid SCHEMBL3605870 | 0.80 | GHSR (0.35) | GHSRCYP2D6SOAT2ACAT1SOAT1 | |
| SCHEMBL3618049 | 0.80 | XIAP (0.37) | XIAP | |
| SCHEMBL3613400 | 0.80 | CYP2D6 (0.31) | XIAPGHSRCYP2D6 | |
| Hydrochloric Acid SCHEMBL3608122 | 0.79 | GHSR (0.32) | XIAPGHSRCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100022582-A1 | Tetrahydroisoquinoline Compound and Medicinal Use Thereof | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2010-01-28 | — | — | US | claimed |
| EP-1857444-A1 | TETRAHYDROISOQUINOLINE COMPOUND AND MEDICINAL USE THEREOF | Kyoto Pharmaceutical Industries, Ltd. (JP) | 2007-11-21 | — | — | EP | claimed |
| US-20100022582-A1 | Tetrahydroisoquinoline Compound and Medicinal Use Thereof | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2010-01-28 | — | — | US | disclosed |
| EP-1857444-A1 | TETRAHYDROISOQUINOLINE COMPOUND AND MEDICINAL USE THEREOF | Kyoto Pharmaceutical Industries, Ltd. (JP) | 2007-11-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022582-A1 | Tetrahydroisoquinoline Compound and Medicinal Use Thereof | ACAT1, ACAT2, LCAT | XIAP 934/4885GHSR 4556/4885CYP2D6 615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.